Amgen Inc. shares fall 1.03% premarket after Roche's mixed clinical trial results for COPD drug.

Amgen Inc. fell 1.03% in premarket trading. The decline is likely due to the mixed results from Roche's clinical trials for astegolimab, a drug candidate for chronic obstructive pulmonary disease. While a midstage trial met its primary goal, a late-stage study did not, causing uncertainty about the drug's future. Roche plans to discuss the data with regulatory authorities to evaluate next steps.